Cerenome closed at $0.89 on Nov 4, down 31.42%, within 0.0% of its lowest close since Sep 11. Volume of 2.5M shares was 1.61× its 20-day average (above normal).
Split-adjusted performance: -43.9% over one month.
Short interest was 782.1K shares at the Oct 15 settlement, up 4.4% from the prior report (0.5% of float, 3.5 days to cover).
No reported quarters with price history yet.
Percentile among 110 companies (100 = best)
Industry medians: 6-month return −4.0%, revenue growth +8.9%, net margin −8.2%, P/E 30.5×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| CNSYCerenome | $0.8916 | −31.42% | — | — | — | — | $6.8M | |
| INBSIntelligent Bio Solutions | $1.75 | −1.13% | −27.4% | +35.8% | −341.0% | — | $5.8M | Compare |
| SNOASonoma Pharmaceuticals | $1.11 | −2.63% | −6.7% | +59.6% | −5.2% | — | $5.3M | Compare |
| NMTCNeuroOne Medical Technologies | $0.9500 | −3.06% | −77.9% | +16.3% | −101.7% | — | $8.7M | Compare |
| TNONTenon Medical | $1.91 | +1.06% | −92.7% | +126.8% | −316.7% | — | $5.1M | Compare |
| NVNOenVVeno Medical | $7.00 | −2.43% | −30.5% | — | — | — | $4.9M | Compare |
| ICUSeaStar Medical Holding | $2.04 | +2.00% | −58.1% | +82.0% | −606.5% | — | $10.8M | Compare |
| AEMDAETHLON MEDICAL | $5.75 | −0.86% | −51.7% | — | — | — | $4.1M | Compare |
| FEMYFemasys | $1.44 | +2.86% | −84.1% | −18.9% | −1346.8% | — | $12.1M | Compare |
No recent articles focused on Cerenome. 2 articles mention it in passing.
Cerenome Inc is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company's CNSide Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
